The fifth edition of the World Health Organization Classification of Tumours of the Central
Nervous System (WHO CNS5) published in 2021 builds on the 2016 edition and …

MYC-driven medulloblastoma (MB) is an aggressive pediatric brain tumor characterized by
therapy resistance and disease recurrence. Here, we integrated data from unbiased genetic …

Medulloblastoma is the most common malignant brain tumor in children. Over the last few
decades, significant progress has been made in revealing the key molecular underpinnings …

Importance Medulloblastoma recurrence in patients who have previously received
irradiation has a dismal prognosis and lacks a standard salvage regimen. Objective To …

A hallmark of high-risk childhood medulloblastoma is the dysregulation of RNA translation.
Currently, it is unknown whether medulloblastoma dysregulates the translation of putatively …

Background Less than 5% of medulloblastoma (MB) patients survive following failure of
contemporary radiation-based therapies. Understanding the molecular drivers of …

Nowadays medulloblastoma (MB) tumors can be treated with risk-stratified approaches with
up to 80% success rate. However, disease relapses occur in approximately 30% of patients …

Background Conventional parameters show limited and unreliable correlations with
medulloblastoma prognosis. Aim To evaluate the factors influencing overall survival (OS) …

Simple Summary Medulloblastoma is the most common malignant childhood brain tumour.
Under standard therapy, relapse occurs in 30% of patients and is almost universally fatal …

Simple Summary Medulloblastoma is the commonest malignant brain tumour of childhood.
Disease relapse following maximal multi-modal therapy including upfront craniospinal …